Complementary and alternative therapies for precancerous lesions of gastric cancer
A protocol for a Bayesian network meta analysis
Tianqi Zhang, MDa, Tiefeng Zhang, MDa,b,∗ Chuancheng Li, MDa, Xixi Zhai, MDa, Qing Huo, PhDc

Abstract
Background: Gastric cancer is one of the most common malignant tumors, which seriously affect people’s health. Precancerous lesions of gastric cancer (PLGC) are a critical stage in the occurrence and development of gastric cancer. Early effective intervention is an important means to prevent and control gastric cancer. In this study, we will evaluate the efficacy and safety of complementary and alternative therapies in the treatment of PLGC by Bayesian network meta-analysis (NMA).

Methods: We will search PubMed, Cochrane Library, CNKI and other databases to gather randomized controlled trials (RCTs) on the treatment of PLGC with complementary and alternative therapies. Two reviewers will screen the literature and extract the data according to the inclusion and exclusion criteria, and then assess the quality and bias risk according to Cochrane’s Risk of Bias Assessment Tool. Bayesian network meta-analysis will be conducted by Stata16.0 and WinBUGS1.4.3.

Results: This study will compare and rank the efficacy and safety of different complementary and alternative therapies for PLGC.

Conclusion: This study can provide reliable evidence for the efficacy and safety of complementary and alternative therapies in treatment of PLGC. We expect to provide scientific and rigorous evidence support for clinicians and patients, and then assist them to choose the optimum treatment.

Protocol registration number: INPLASY2020120077.

Abbreviations: CI = confidence interval, GRADE = grading of recommendations assessment development and evaluation, MeSH = medical subject headings, OR = odds ratio, PLGC = precancerous lesion of gastric cancer, RCT = randomized controlled trials, SMD = standardized mean difference.

Keywords: Bayesian, complementary and alternative therapies, network meta-analysis, precancerous lesion of gastric cancer, protocol

1. Introduction

Gastric cancer is still a worldwide problem. In the latest global cancer statistics, the incidence of gastric cancer is the fifth in the world, and cancer-related mortality ranks third in the world.[1,2] Although it is possible to identify and treat gastric cancer, most cases are diagnosed at an advanced stage. The cure rate of early gastric cancer is high, and the 5-year survival rate can reach over 90%.[3] PLGC is mainly characterized by gastric mucosal dysplasia and intestinal metaplasia, which usually includes chronic atrophic gastritis, gastric polyps, gastric ulcer, residual gastritis and other diseases. Most potential patients do not attach much importance to understanding the prevention and treatment of PLGC. Timely intervention in PLGC stage is of great significance to delay the progress of the disease and even reversing the disease. Hence, early diagnosis and effective prevention and treatment of PLGC have proved to be an important topic for many medical workers.

Relevant study has confirmed that Helicobacter pylori infection is related to chronic gastritis, intestinal metaplasia and gastric cancer.[4] Therefore, anti-Helicobacter pylori treatment should be carried out in time according to the doctors advice. Eradication of Helicobacter pylori infection can alleviate, control or delay gastric mucosal atrophy and intestinal metaplasia, and reverse gastric mucosal dysplasia. Endoscopic
therapy is an effective means to reverse or even eradicate gastric mucosal dysplasia. At present, modern medicine still lacks drugs with clear curative effect and ideal treatment methods for PLGC, mainly including follow-up and monitoring, regular examination. Once severe dysplasia or even cancerous lesions are found, timely surgery or local gastric mucosal resection will be performed. In 2019, the latest European PLGC management consensus listed Helicobacter pylori eradication therapy as a treatment with high quality evidence. Other medical treatments include COX inhibitors, antioxidant, non-steroidal drugs, increasing mucosal nutrition and gastric mucosal protection, improving gastric motility, inhibiting bile reflux and other symptomatic treatments, and their efficacy remains to be discussed. But for chronic atrophic gastritis and precancerous lesions, there is no ideal intervention and treatment. Therefore, it is urgent to adopt various methods and standardized treatment to control its occurrence and development.

In recent years, complementary and alternative therapies have achieved prominent clinical effects in treating PLGC, which mainly include Chinese herbal medicine, acupuncture, massage, acupoint injection, psychotherapy, exercise therapy and so on. Modern pharmacological studies have shown that TCM has the functions of protecting gastric mucosa, resisting oxidation, regulating cell proliferation and regulating immunity. Besides, studies have shown that acupuncture and moxibustion has achieved satisfactory effects in improving symptoms by protecting gastric mucosa, regulating immunity and cell proliferation. What’s more, acupoint application can make use of strengthening the gastric mucosal barrier, repairing gastric mucosal injury, regulating cell proliferation and apoptosis to prevent and treat atrophic gastritis. In addition, studies have manifested that drug therapy combined with appropriate psychotherapy can achieve pleasing effect in treating mood-related chronic gastric diseases. Through targeted psychological counseling, patients can have a correct understanding of the disease, eliminate their fear of cancer, build confidence in overcoming the disease, and better cooperate with doctors, so as to improve clinical curative effect and improve the quality of life of patients.

In order to select the best treatment, this study will conduct NMA to compare these treatments. This study expands the total sample size by means of combining other relevant RCTs to minimize the bias. Significantly, Bayesian NMA is better than traditional analysis in comparing multiple treatments while the latter usually compares 2 interventions. Furthermore, NMA can combine direct and indirect comparisons, and therefore we can utilize it to select the optimal treatment for the patients with PLGC.

2. Methods

2.1. Study registration

This protocol has been registered on the international platform of registration system evaluation and meta-analysis agreement. (Registration number: INPLASY2020120077; URL= https://inplasy.com/inplasy-2020-12-0077/). We will conduct it strictly in accordance with the Preferred Reporting Items for Systematic Review and Meta-Analysis Protocols (PRISMA-P).

2.2. Eligibility criteria

2.2.1. Type of study. This study will contain all relevant peer-reviewed randomized controlled trials (RCTs). Review, animal study, case report, conference paper will not be included. The sample size of both treatment group and control group is at least 30. The language will be confined to Chinese or English.

2.2.2. Participants. Patients who meet the diagnostic criteria of precancerous lesion of gastric cancer (PLGC); There are no restrictions in gender, age, race and nationality. Patients with other complicated and severe diseases will not be included.

2.2.3. Interventions. PLGC patients in the treatment group are given complementary and alternative therapies, which include Chinese herbal medicine, acupuncture, massage, acupoint injection, psychotherapy, exercise therapy and so on. Different complementary and alternative therapies can be freely combined. In addition, they can be adopted based on routine western medicine or separately.

2.2.4. Comparisons. The control group will adopt conventional western medicine, placebo, or other positive drugs. There is no restriction on the dosage form.

2.2.5. Outcomes.

1. The main outcomes: clinical efficacy rate, Helicobacter pylori infection clearance rate;
2. Secondary outcomes: the improvement rate of gastroscopy, the improvement rate of gastric mucosa pathology, Traditional Chinese Medicine Syndrome Score Scale (TCMSSS), the incidence of adverse events, economic costs.

2.3. Exclusion criteria

1. Repeated published literature;
2. Animal experiments, reviews, case reports, etc;
3. Combined with other complicated and severe diseases that have great interference in research;
4. Selected literature with different baseline data, incomplete data;
5. Literature with low quality.

2.4. Databases and search strategy

We will carefully discuss the details and precautions about literature retrieval, and then ascertain the search strategy after pre-retrieving literature. We will utilize a combination of MeSH and free-text terms. The retrieval time is from the establishment of the database to December 2020. All patients qualified in the trial are diagnosed as PLGC by clinical and endoscopic pathology. Search databases are as follows: PubMed, Cochrane Library, Cochrane Controlled Trial Center Registration, EMBASE, Web of Science, CNKI, Wanfang database, VIP database. In addition, we will proceed to follow up the literature in systematic review/meta-analysis. The search scheme of PubMed database is shown in Table 1.

2.5. Data extraction

On the basis of the above strategy, we will retrieve all relevant literature from the database, and then import them into EndNote X9. Two researchers (Tianqi Zhang and Xixi Zhai) will browse the title and abstract separately, sort out the literature according to the inclusion and exclusion criteria, and then extract the data. Based on the previous step, qualified literature will be further
searched. If the 2 researchers have different opinions, they will discuss and solve them or hand over to the third researcher (Chuancheng Li) for assistance. If the collected literature is incomplete, we will attempt to consult the corresponding author for help. The data of literature are extracted as follow:

1. Basic information: title, author, journal, year, trial registration number, country, etc.
2. Participants: gender, age, sample size, duration, etc.
3. Intervention: treatment method, frequency, dose, duration, etc.
4. Outcomes: The main outcomes include clinical efficacy rate, Helicobacter pylori infection clearance rate; Secondary outcomes include the improvement rate of gastroscopy, the improvement rate of gastric mucosa pathology, Traditional Chinese Medicine Syndrome Score Scale (TCMSSS), the incidence of adverse events, economic costs, etc.

2.6. Risk of bias analysis

The methodological quality will be evaluated by 2 researchers independently in the light of the Cochrane Collaboration’s Risk of Bias Tool, which contains 7 items and every item is classified as “high” “unclear” and “low” levels.

2.7. Assessment of heterogeneity

We will utilize $I^2$ statistics to assess the heterogeneity of each pairwise comparisons. When $I^2 < 50\%$ and $P > .10$, we will adopt the fixed effect model since there is no significant heterogeneity. If not, we will perform a random effect model. Subgroup analysis and sensitivity analysis are needed for heterogeneity caused by factors such as trial design and treatment duration. In addition, supposing that the origin of heterogeneity is unaware, only descriptive analysis will be used.

2.7.1. Subgroup analysis. Considering the heterogeneity, we will perform subgroup analysis in the light of the characteristics of research related to the source of heterogeneity. In addition, with regard to different design schemes, we will adopt subgroup analysis in accordance with age, gender, treatment type and course of disease.

2.7.2. Sensitivity analysis. Sensitivity analysis will be assessed by excluding the literature one by one to ascertain whether the literature has an impact on heterogeneity. Once the heterogeneity of the study changes, this article may be the source of heterogeneity, and further analysis will be carried out, such as the difference in sample size and the reference standard of outcome indicators. If there is no obvious change before and after exclusion, it manifests that the results are stable and credible.

2.8. Statistical analysis

2.8.1. Pairwise meta-analysis. We will execute STATA16.0 for pairwise meta-analysis. Continuous results will be summarized by SMD with 95% CI while dichotomous results will be analyzed by OR with 95% CI. $I^2$ will be adopted to evaluate the heterogeneity of each pairwise comparisons.

2.8.2. NMA. NMA will be implemented by STATA 16.0 and WinBUGS1.4.3 to synthesize direct and indirect evidence. The Bayesian NMA is mainly on the basis of the Markov-chain-Monte-Carlo (MCMC), so we will apply the MCMC in WinBUGS1.4.3 to execute Bayesian NMA of random effect model. After statistical analysis, the potential scale reduction factor (PSRF) is used to measure the convergence. When it is closer to 1, the convergence is much better, and the conclusion is more credible. Besides, we will adjust iteration times and annealing times based on the actual situation, and estimate the corresponding effective value of 95% CI. Moreover, this study will adopt surface under the cumulative ranking curve values to predict and rank the order of therapeutic effect. If the area under the curve is larger, the therapeutic effect is better. Furthermore, we will analyze the consistency of the main indicators. Supposing there is a closed loop, we will apply the node splitting method to estimate each loops inconsistency.

2.9. Publication bias

When talking about the potential publication bias, if each subgroup contains no less than 10 trials, this study will adopt funnel plot for analysis. The impact of publication bias can be evaluated by observing its symmetry. Assuming that the funnel chart is symmetrical, it demonstrates that there is no significant
publications bias. Otherwise, it manifests that there may be publication bias, and then we will discuss the reasons.

2.10. Evaluation of evidence quality

In this study, GRADE method will be utilized to assess the quality of evidence and the strength of recommendations.[19] The quality of the evidence means that people can decide the accuracy of the predicted value, which can be classified as high, medium, low and very low. The basic application principle of GRADE method in NMA mainly includes 5 aspects, namely, the research limitation, inconsistency, indirectness, publication bias and inaccuracy.

3. Discussion

PLGC is considered to be a crucial phase in the early diagnosis and prevention of intestinal gastric cancer.[20] It takes a relatively long process for PLGC to develop into gastric cancer. Due to active follow-up monitoring and effective intervention, the development of gastric cancer is blocked, and the incidence and mortality of gastric cancer will be significantly reduced.[21] Modern medical examination methods play an important role in the diagnosis of PLGC and early detection of lesions can be achieved.[22,23] However, there is no ideal intervention and treatment measures for PLGC, and drug treatment is still controversial. Thus, complementary and alternative therapies are getting more and more attention.

Complementary and alternative therapies have achieved remarkable results in PLGC. As a comprehensive treatment method for PLGC, TCM is increasingly shown its advantages in treatment, reflecting the concept of “preventing disease”, and also the content of preventive medicine. With the guidance of TCM theory, TCM can intervene at multiple targets and levels to treat PLGC by protecting gastric mucosa, regulating immunity, affecting cell proliferation and differentiation, and anti-oxidation.[24,25] Moreover, PLGC has gained more and more international recognition by treating it with TCM.[26] Acupuncture and moxibustion have the characteristics of safety, simplicity, low cost and few side effects, and can significantly improve the clinical symptoms of patients.[27] In addition, drug therapy combined with psychotherapy and exercise therapy can relieve patient psychological pressure, relieve their emotions, and mortality of gastric cancer will be significantly reduced.[21]

NMA mainly includes 5 aspects, namely, the research limitation, inconsistency, indirectness, publication bias and inaccuracy.

Author contributions

Conceptualization: Tianqi Zhang, Tiefeng Zhang, Qing Huo.
Formal analysis: Tianqi Zhang, Tiefeng Zhang.
Methodology: Chuancheng Li, Xixi Zhai.
Project administration: Tiefeng Zhang.
Software: Tianqi Zhang, Chuancheng Li.
Writing – original draft: Tianqi Zhang, Tiefeng Zhang.
Writing – review & editing: Tianqi Zhang, Tiefeng Zhang.

References

[1] Bray F, Ferlay J, Soerjomataram I, et al. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA 2018;68:394–424.
[2] Smyth EC, Nilsson M, Grabsch HI, et al. Gastric cancer. Lancet 2020;396:635–48.
[3] Katai H, Ishikawa T, Akazawa K, et al. Five-year survival analysis of surgically resected gastric cancer cases in Japan: a retrospective analysis of more than 100,000 patients from the nationwide registry of the Japanese Gastric Cancer Association (2001-2007). Gastric Cancer 2018;21:144–54.
[4] Mera RM, Bravo LE, Camargo MC, et al. Dynamics of Helicobacter pylori infection as a determinant of progression of gastric precancerous lesions: 16-year follow-up of an eradication trial. Gut 2017;gutjnl-2016-311685:1–2.
[5] Pimentel-Nunes P, Dinis-Ribeiro M. Endoscopic submucosal dissection in the treatment of gastrointestinal superficial lesions: follow the guidelines!. Ge Port J Gastroenterol 2015;32:184–6.
[6] Talebi Bezmim Abadi A, Yamaoka Y. Helicobacter pylori infection as a determinant of progression of gastric precancerous lesions: follow the guidelines!. J Glob Antimicrob Resist 2018;14:111–7.
[7] Pimentel-Nunes P, Libânia D, Marcos-Pinto R, et al. Management of epithelial precancerous conditions and lesions in the stomach (MAPS II): European Society of Gastrointestinal Endoscopy (ESGE), European Helicobacter and Microbiota Study Group (EHMSG), European Society of Pathology (ESP), and Sociedade Portuguesa de Endoscopia Digestiva (SPEd) guideline update 2019. Endoscopy 2019;51:365–88.
[8] Cai T, Zhang C, Zhao Z, et al. The gastric mucosal protective effects of astragaloside IV in mns-induced GPL rats. Biomed Pharmacother 2018;104:291–9.
[9] Gu Z, Ling J, Cong J, et al. A review of therapeutic effects and the pharmacological molecular mechanisms of Chinese medicine weilichun in treating precancerous gastric conditions. Integrative Cancer Therapies 2020;19:1534735420953215.
[10] Li Z, Zhang H, Wang D, et al. Research progress on mechanism of acupuncture for chronic atrophic gastritis. Chin Acupunct Moxibustion 2016;36:1117–9.
[11] Wang L, Li G. Warm acupuncture for chronic atrophic gastritis with spleen-stomach deficiency cold. Chin Acupunct Moxibustion 2017;37:135–8.
[12] Yang Z, Wang C, Chen J, et al. Effects of moxibustion on cell proliferative factors in gastric mucosa in rats with precancerous lesions of chronic atrophic gastritis. Chin Acupunct Moxibustion 2015;35:1269–73.
[13] Yuhong L. Zhiling huazhuo jiedu decoction combined with acupuncture application therapy and effect of cag on gastric motility and inflammatory factor levels. Chin Arch Tradit Chin Med 2018;36:2281–3.
[14] Sun Y, Wang S, Qi M, et al. Psychological distress in patients with chronic atrophic gastritis: the risk factors, protection factors, and cumulative effect. Psychol Health Med 2018;23:1–7.
Zhao X, Wu M, Zhang D, et al. The relationship of interpersonal sensitivity and depression among patients with chronic atrophic gastritis: the mediating role of coping styles. J Clin Nurs 2018.

Moher D, Shamseer L, Clarke M, et al. Preferred reporting items for systematic review and meta-analysis protocols (PRISMA-P) 2015 statement. Syst Rev 2015;4:1.

Cumpton M, Li T, Page MJ, et al. Updated guidance for trusted systematic reviews: a new edition of the Cochrane Handbook for Systematic Reviews of Interventions. Cochrane Database Syst Rev 2019;10:1–2.

Lunn DJTA, Best N, et al. WinBUGS: a Bayesian modelling framework: concepts, structure, and extensibility. Stat Comput 2000;10:325–37.

Puhan MA, Schunemann HJ, Murad MH, et al. A GRADE Working Group approach for rating the quality of treatment effect estimates from network meta-analysis. BMJ 2014;349:g5630.

Zhao Z, Yin Z, Wang S, et al. Meta-analysis: The diagnostic efficacy of chromoendoscopy for early gastric cancer and premalignant gastric lesions. J Gastroenterol Hepatol 2016;31:1539–45.

Badle A. Long-term follow-up after endoscopic resection of gastric superficial neoplastic lesions in Portugal. Endoscopy 2014;46:933–40.

Lim H, Jung H, Park Y, et al. Discrepancy between endoscopic forceps biopsy and endoscopic resection in gastric epithelial neoplasia. Surg Endosc 2014;28:1256–62.

Ho SWT, Tan P. Dissection of gastric cancer heterogeneity for precision oncology. Cancer Ence 2019;110:1–6.

Xu J, Shen W, Pei B, et al. Xiao Tan He Wei Decoction reverses MNNG-induced precancerous lesions of gastric carcinoma in vivo and vitro: Regulation of apoptosis through NF-κB pathway. Biomed Pharmacotherapy 2018;108:95–102.

Zhao Y, Li B, Wang G, et al. Dendrobium officinale polysaccharides inhibit 1-Methyl-2-Nitro-1-nitrosoguanidine induced precancerous lesions of gastric cancer in rats through regulating Wnt/F-B-catenin pathway and altering serum endogenous metabolites. Molecules (Basel, Switzerland) 2019;24:1–14.

Tang X, Zhou L, Zhang S, et al. Randomized double-blind clinical trial of Moluodan for the treatment of chronic atrophic gastritis with dysplasia. Chin J Integrative Med 2016;22:9–18.

Liu C, Chen J, Chang X, et al. Comparative metabolomics study on therapeutic mechanism of electro-acupuncture and moxibustion on rats with chronic atrophic gastritis (CAG). Sci Rep 2017;7:14362.

Xia L, Yanli Z. Effect of group psychotherapy on quality of life and emotional state of patients with gastric cancer. Doctor 2018;3:97–8.